Integra LifeSciences Announces Launch of Luxtec MLX 300W Xenon Light Source; Will Feature Product At Upcoming ACS Meeting
PLAINSBORO, N.J., Oct. 13, 2008 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today the introduction of the Luxtec(R) MLX 300W Xenon light source for use in surgical procedures, the latest addition to Luxtec’s extensive line of illumination systems. Integra will feature the Luxtec(R) MLX light source at the American College of Surgeons 94th Annual Clinical Congress, October 12-15, 2008, San Francisco, California.
The Luxtec(R) MLX 300W Xenon light source system has received 510(k) clearance from the United States Food and Drug Administration to be marketed in the United States. The Luxtec(R) MLX 300W Xenon light source, along with a robust group of companion light sources, light guides and recording options, will be marketed globally through the Integra Surgical sales network.
The Luxtec(R) MLX light source is the culmination of many years of development and expertise. It provides an unprecedented 1,000 hour lamp warranty, an increase of over 50% from current technology. The Luxtec(R) MLX light system also provides new Smart Fan Technology, which enhances system cooling and improves unit performance. New touchpad controls offer surgeons unmatched repeatability and precision in light output on the surgical site. The Luxtec(R) MLX light source can accommodate most fiber optic surgical headlights.
Most surgical procedures require directed white light to visualize blood vessels, muscle tissue and specific anatomical features. Over 60,000 surgeons worldwide use Luxtec(R) light sources for optimal surgical site visualization.
“The MLX light source takes the Luxtec(R) surgical lighting products to new levels of brightness, control and operational cost savings, and will become the focus and centerpiece of Integra Surgical Illumination sales,” said Bob Perrett, President of the Integra Medical Instrument Group. “The quality and color correctness of this light is remarkable and differentiated from even higher powered units.”
Integra Surgical is a leading provider of Jarit(R) brand surgical instruments used in general surgery, neurosurgery, cardiac surgery and most other surgical modalities, as well as the Luxtec(R) illumination products produced in the USA at company-owned facilities. Integra Surgical’s direct selling effort in the United States involves more than 30 sales professionals, as well as a select group of high performing historical dealers. In international markets, Integra Surgical products are sold through a network of distributors. http://www.integra-surgical.com/
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing and marketing of cost-effective surgical implants and medical instruments. The company’s products are used to treat millions of patients every year, primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery. Integra’s headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. www.Integra-LS.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the Luxtec(R) MLX 300W Xenon light source. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use this product may affect the prospects for its use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading “Risk Factors” included in section IA of Integra’s Annual Report on Form 10-K for the year ended December 31, 2007 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
This news release was distributed by GlobeNewswire, www.globenewswire.com
CONTACT: Integra LifeSciences Holdings Corporation John B. Henneman, III, Executive Vice President, Finance and Administration, and Chief Financial Officer (609) 936-2481 jhenneman@Integra-LS.com Gianna Sabella, Public Relations Manager (609) 936-2389 gsabella@integra-LS.com